For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com. It has approximately 16,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Astellas Contacts: For Media Chris Goldrick Associate Director, Portfolio Communications (847) 224-3014 chris.goldrick@astellas.com. Astellas Contacts: For Media: Chris Goldrick 847-224-3014 chris.goldrick@astellas.com. In the next few years, Astellas will face the expiration of patents for several major For Media and Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com Astellas Contacts: For Media Chris Goldrick Associate Director, Portfolio Communications (847) 224-3014 chris.goldrick@astellas.com For Investors Astellas Pharma Inc. Corporate Advocacy & Relations TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 Source: Seagen Inc. … For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com. Media Inquiries: Jennifer Harrington +1.610.574.9196 REFERENCES 1 Akizawa T, Iwasaki M, Otsuka T, et al. TENDANCE . We are promoting the Focus Area Approach that is designed to identify … For Media and Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com Astellas Contacts: For Media Chris Goldrick Associate Director, Portfolio Communications (847) 224-3014 chris.goldrick@astellas.com For Investors Astellas Pharma Inc. Corporate Advocacy & Relations TEL: +81-3-3244-3201 FAX: +81-3-5201-7473. This acquisition marks the successful outcome of a collaboration agreement … For Investors Shin Okubo 81-3-3244-3202 shin.ohkubo@astellas.com. Astellas: For Media Chris Goldrick 847-224-3014 chris.goldrick@astellas.com . Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication Astellas Pharma US pilots pharma efforts that are outta this world. 1 Astellas Way. Phone (800) 888-7704 . Astellas Contacts: For Media Marjorie Moeling Director, Corporate Affairs (224) 205-5205 marjorie.moeling@astellas.com. For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com. See other locations. In depth view into ALPMY (Astellas Pharma) stock including the latest price, news, dividend history, earnings information and financials. Phone +81-332443000. sustaina esg評価について sustaina esg評価はesgレーティングをクラス分けした評価情報です。sustaina esgレーティングがaaa、aa、aの場合「高位」、bbb、bb、bの場合「中位」、ccc、cc、c、dの場合「低位」、評価が無い場合「--（未評価）」を表示しています。 森纳尔（Mark Reisenauer）说，“我们不知道的是，我们的生活会发生多么大的改变。 CEO Message 2 Corporate Strategy 6 Philosophy 8 VISION & Strategy 10 Strategic Plan 2018 13 CSR-Based Management 18 Materiality in CSR Activities 21 Contributions to the Sustainable Development Goals 26 Corporate Governance 29 Corporate Governance 31 Board of Directors 33 Risk Management 42 Business Review 45 Top Management 47 Focus Area Approach 49 Pipeline Projects 63 Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. Address. ä¼šã¨2016年度の配当予想、有価証券報告書等の掲載についてお知らせします。 For Investors Shin Okubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com Astellas Pharma is one of the largest prescription drug companies in Japan. For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research. chris.goldrick@astellas.com For Investors Astellas Pharma Inc. Corporate Advocacy & Relations TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 Source: Seagen Inc. Serious News for Serious Traders! For Investors Ryan Crowe 212-733-8160 ryan.crowe@pfizer.com . Sébastien Desprez – VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.com. No securities transactions are negotiated or executed through AskForFunding.com, and we receive no compensation in connection with the purchase or sale of securities. 1. … 発行日：2013å¹´5月20日 アステラスメールマガジンです。 今回は5月13日に発表しました2013å¹´3月期 決算概況についてお知らせします。 Astellas Contacts: For Media Chris Goldrick Associate Director, Portfolio Communications (847) 224-3014 chris.goldrick@astellas.com. For Investors Shin Ohkubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com By using this website you acknowledge that you … A Phase 3, Multicenter, Randomized, Open-label, Active Comparator Conversion … For further information: Astellas Contacts: For Media, Chris Goldrick, Associate Director, Portfolio Communications, (847) 224-3014, chris.goldrick@astellas.com, or For Investors, Astellas Pharma Inc., Corporate Advocacy & Relations, TEL: +81-3-3244-3201, FAX: +81-3-5201-7473; or for Seagen Contacts: For Media and Investors, Peggy Pinkston, Vice President, Investor Relations, … 2-5-1, NIHOMBASHIHONCHO. Astellas Pharma Inc. is a Japan-based pharmaceutical company that operates its business in more than 70 countries around the world. Company Description. Astellas Contacts: For Media Marjorie Moeling Director, Corporate Affairs (224) 205-5205 marjorie.moeling@astellas.com. ä¼šã¨2014年度の配当予想、有価証券報告書等掲載についてお知らせします。 For Investors Shin Ohkubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com CHUO-KU , TOKYO, 103-0023 Japan. For Investors Shin Ohkubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com Northbrook , IL, 60062-6111 United States. For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com Astellas Contacts: For Media Marjorie Moeling Director, Corporate Affairs (224) 205-5205 marjorie.moeling@astellas.com For Investors Shin Okubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com Address. Investor Relations: Juli P. Miller, Ph.D. – Senior Director, Investor Relations T: +1 215 825 9310 M: +1 215 460 8920 Juli.Miller@adaptimmune.com. See other locations. For Investors Peggy Pinkston Vice President, Investor Relations (425) 527-4160 ppinkston@seagen.com. Company Description . For Investors: Ryan Crowe 212-733-8160 Ryan.Crowe@pfizer.com. Corporate Strategy / Investor Relations 1.415.978.1434 mtung@fibrogen.com. The company's main products include prostate cancer drug XTANDI, overactive bladder treatments VESIcare and Betanis/Myrbetriq/BETMIGA, and organ … Source: Pfizer Inc. AskForFunding.com is not a crowdfunding platform. www.astellas.com. Astellas Contacts: For Media Chris Goldrick Associate Director, Portfolio Communications (847) 224-3014 chris.goldrick@astellas.com. For Investors: Shin Okubo 81-3-3244-3202 shin.ohkubo@astellas.com About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. TOKYO and NORTHBROOK, Ill., Dec. 14, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc. ("Potenza") on December 13, 2018, U.S. Eastern Time. www.astellas.com. Investors: Michael Tung, M.D. Investor Enquiries UK: Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032 Karl Hard +44 207 304 5322 mob: +44 7789 654364. For Investors Shin Okubo Executive Director, Investor Relations +81-3-3244-3202 shin.ohkubo@astellas.com We make no recommendation that any investor make any particular investment, or that any company offer any securities. We will achieve sustainable growth by producing medical solutions that provide VALUE to patients. Investor Enquiries US: Ed Seage +1 302 886 4065 mob: +1 302 373 1361 Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043